Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing- Remitting Multiple Sclerosis

• DOI: 10.1371/journal.pone.0130715
• Publication Date: 2015-06-25T18:36:01Z
• Authors: Roberta Mancuso; Ambra Hernis; Simone Agostini; Marco Rovaris; Domenico Caputo; Dietmar Fuchs; Mario Clerici
• Keywords: Indoleamine 2,3-dioxygenase; Relapsing remitting; Expression (computer science)

Background Interferon gamma (IFN-γ) production induces the transcription of indoleamine 2,3 dioxygenase (IDO) resulting in reduction T-cell activation and proliferation through depletion tryptophan elicitation Treg lymphocytes. IDO was shown to be involved pathogenesis autoimmune diseases; we investigated whether changes gene expression activity could indicative onset relapse multiple sclerosis (MS) patients. Methods interferon-γ expression, serum (Kynurenine/Tryptophan ratio) neopterin concentration – a protein released by macrophages upon IFN-γ stimulation were measured 51 individuals: 36 relapsing remitting (RR)-MS patients (21 acute phase -AMS, 15 stable -SMS) healthy controls (HC). PBMCs samples AMS collected before (BT-AMS) during glucocorticoids-based therapy (DT-AMS). Results increased decreased (p<0.001) BT-AMS compared SMS Glucocorticoids-induced disease remission resulted significant catalytic (p<0.001). Serum followed same trend as activity. Conclusions Measurement blood useful marker monitor clinical course RR-MS. Therapeutic interventions modulating may beneficial MS.